Double-Targeting immune cells tested in kids with tough leukemia
NCT ID NCT03330691
Summary
This early-stage study is testing a new type of personalized immune cell therapy for children and young adults with a specific type of leukemia that has come back or hasn't responded to other treatments. Doctors take a patient's own immune cells (T-cells), modify them in a lab to recognize and attack two specific markers (CD19 and CD22) on the leukemia cells, and then infuse them back into the patient. The main goals are to see if this two-target approach is safe to give and if researchers can reliably make enough of these modified cells to treat patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Children's and Women's Health Centre of British Columbia
Vancouver, British Columbia, V6H 3V4, Canada
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.